ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq.
ImmunOs Therapeutics is a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.
The proceeds will be used to fund the clinical development of ImmunOs’ lead program, IOS-1002 (formerly iosH2), through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs within the Company´s HLA-based pipeline towards clinical development. Additionally, ImmunOs has established a U.S. subsidiary to further expand its international reach, execute future U.S. clinical trials, and strengthen its transatlantic operations and team.
Walder Wyss advises Gimv, a European investment company listed on Euronext Brussels partnering with entrepreneurial and innovative companies in forward-looking investment áreas. The Walder Wyss team includes partner Alexander Gutmans (corporate/m&a and venture capital, pictured left) and Karina Tschon (associate, corporate/m&a and venture capital, pictured right).
Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. The team consisted of Beat Kühni (pictured), Simone Ehrsam and Tobias Weber (all corporate/m&a), Lukas Aebi (tax), Elena Furlanetto (employment) and Vera Vallone (IP).
